Copycats wanted: Pfizer, AZ and more under threat as China solicits generics The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives.
2019 CHPI Exhibition in Shanghai
EU expands look at Zhejiang Huahai as impurities show up in other 'sartans' A global recall may get expanded beyond valsartan as regulators continue to find potentially cancer-causing impurities in other “sartan” products. European regulators say they have found the same impurity discovered in valsartan in both losartan made by Hetero Labs and now irbesartan by Aurobindo Pharma.